Adherence, patient preference and dosing frequency: understanding the relationship.
about
Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adherenceOptimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.Once-weekly albiglutide in the management of type 2 diabetes: patient considerations.Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial.More Favorable Metabolic Impact of Three-Times-Weekly versus Daily Growth Hormone Treatment in Naïve GH-Deficient ChildrenWhat Matters to Women When Making Decisions About Breast Cancer Chemoprevention?Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trialIntravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect.Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial.Factors Associated with Persistence with Teriparatide Therapy: Results from the DANCE Observational StudyFinal results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.Osteoporosis medication profile preference: results from the PREFER-US studyUnderstanding patient preferences and willingness to pay for hemophilia therapies.Do we prescribe what patients prefer? Pilot study to assess patient preferences for medication regimen characteristics.Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preferenceDevelopments in the pharmacotherapeutic management of osteoporosis.Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.Treatment of postmenopausal osteoporosis, patient perspectives - focus on once yearly zoledronic acidAdherence and weight loss outcomes associated with food-exercise diary preference in a military weight management program.First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates.Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.The role and efficacy of denosumab in the treatment of osteoporosis: an update.Patient-centredness in integrated healthcare delivery systems - needs, expectations and priorities for organised healthcare systems.Comparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms.PEGylated IFNβ-1a in the treatment of multiple sclerosis.Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015.Open-label, Intermittent Dose, Prospective Study Evaluating the Effects of Tadalafil on Lower Urinary Tract Symptoms and Erectile Function in Patients with Benign Prostatic Hyperplasia: Continuation and Durability of Effects.Adherence with urate-lowering therapies among male patients with gout in a routine clinical setting.Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study.Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database.Injectable bisphosphonates for the treatment of osteoporosis.Physician differences in managing postmenopausal osteoporosis: results from the POSSIBLE US™ treatment registry study.Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™.Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients.Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis.
P2860
Q26778291-47D17719-B7D4-44B5-90EE-A9C2D4D2FCA7Q33644812-FE7743AD-FEE9-49D7-AFF4-6871B7A8A295Q33728226-00015957-2D11-4843-8374-32DBDDDEE6F2Q33746674-4FDE9C8B-7CB6-4FD0-98BA-A2E386805398Q33786906-DAE841D8-024D-41BD-AABF-4FBCE0BD4718Q33910927-1F5CD62E-EBCC-454B-849E-9E34D3CF8308Q33914033-4D54336C-1DBD-4247-9603-EA332806E6BDQ33973902-8377F135-6987-421C-B560-F70AE3C3EF3BQ35072496-43CBCB2B-386C-4854-99A0-B908811AFDBDQ35371081-873963BE-6FD6-4D6F-B118-B9BE66075FDDQ35644204-F26778A1-B65D-4345-8B43-F50F1DEFDDEDQ36088579-776FC656-07C7-4570-92F9-8387263C86A6Q36284406-D2870B7E-836D-4E25-ABA1-DF8227D4544DQ36289290-B000051C-712F-48D9-A329-864DC3442AC4Q36396938-5816C549-F05C-4292-9DB9-53821848AD0EQ36548722-76D3A73D-F572-47DF-AE4C-945766BB899FQ37402282-010A43FC-7557-4EC4-A60A-EC3FD8C3E455Q37423723-9CEE6093-D46B-4AA4-B7B8-9AF48351A0B3Q37606630-F16E980D-27E4-4D5C-BAE0-ED47E0938BA4Q37638700-199849D0-EB6D-4DE6-A242-3BBF9AE76C49Q37768696-A055C854-C736-45A6-93D8-8417F2B54874Q37826197-A548D129-99AD-4ADB-8149-D627718E2629Q38401910-D3F13FE3-73F3-4889-9174-4C3143205C60Q38436646-C494DC62-9C6D-46F6-981C-F82EFF2A504AQ38513495-462F00F7-6092-4F5B-9F23-CA0F23D5BA09Q38928600-266D9AF1-E5B4-4719-808A-04675A418BE9Q39275983-3BA3863D-048D-47DC-A664-CD768391B1C1Q40770483-55E6F108-A1F6-4AA7-AAAF-41AF99945457Q42268606-A0BBC8C3-78A2-4225-B508-BC9B39E54B07Q42289113-75906AB9-DCDA-4737-9E08-5228AC85D3A4Q43267037-482618F7-94FC-4CFE-92E5-8513861FB7FEQ45345590-69417934-927A-405E-BBCE-4FE859A5DFA9Q46025463-0CD2BA29-D2C0-4E88-9987-C4696FDC73AAQ46470161-2A4276AF-D40E-406A-8241-3DD65CD7EABFQ50480283-1B854D69-FA3B-4656-A55A-94AB60453DB5
P2860
Adherence, patient preference and dosing frequency: understanding the relationship.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Adherence, patient preference and dosing frequency: understanding the relationship.
@ast
Adherence, patient preference and dosing frequency: understanding the relationship.
@en
type
label
Adherence, patient preference and dosing frequency: understanding the relationship.
@ast
Adherence, patient preference and dosing frequency: understanding the relationship.
@en
prefLabel
Adherence, patient preference and dosing frequency: understanding the relationship.
@ast
Adherence, patient preference and dosing frequency: understanding the relationship.
@en
P2093
P1433
P1476
Adherence, patient preference and dosing frequency: understanding the relationship.
@en
P2093
J Y Reginster
P356
10.1016/J.BONE.2006.01.150
P433
P577
2006-03-07T00:00:00Z